- Patients with COVID-19 who are taking renin-angiotensin system (RAS) inhibitors for hypertension have a significant survival benefit vs those not taking the drugs.
- This meta-analysis found no association between taking RAS inhibitors and COVID-19 severity.
Why this matters
- The findings are in keeping with accumulating evidence that patients taking these drugs should at the least continue on them if they develop COVID-19.
- This growing evidence base should quell concerns and controversy about potential negative effects of RAS inhibitors.
- Patients with hypertension who were taking RAS inhibitors had significantly reduced mortality vs those not taking them:
- OR, 0.57 (95% CI, 0.38-0.84; P=.004; I2=0).
- The patient groups did not differ, however, in COVID-19 severity:
- OR, 0.71 (95% CI, 0.46-1.08; P=.11; I2=59%).
- No significant publication bias was detected.
- The authors conducted a meta-analysis on data from 9 observational studies that included 3936 patients with both hypertension and COVID-19.
- Primary outcome: COVID-19 severity.
- Secondary outcome: COVID-19 mortality.
- Studies were published up to May 13, 2020.
- Funding: National Natural Science Foundation of China; Zhejiang Provincial Natural Science Foundation of China.
- Fairly high heterogeneity among the studies regarding severity outcome.
- All included studies were observational, although judged as high quality.